Total Payments
$1,354
2024 Payments
$69.88
Companies
30
Transactions
64
Medicare Patients
5,376
Medicare Billing
$6.9M
Payment Breakdown by Category
Food & Beverage$1,290 (95.3%)
Education$63.68 (4.7%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $1,290 | 60 | 95.3% |
| Education | $63.68 | 4 | 4.7% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $132.41 | 6 | $0 (2023) |
| Zimmer Biomet Holdings, Inc. | $104.00 | 1 | $0 (2022) |
| Mirati Therapeutics, Inc. | $100.67 | 4 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $93.30 | 5 | $0 (2024) |
| PFIZER INC. | $88.52 | 5 | $0 (2023) |
| Merck Sharp & Dohme LLC | $68.00 | 2 | $0 (2022) |
| Janssen Biotech, Inc. | $62.19 | 3 | $0 (2022) |
| EISAI INC. | $56.38 | 3 | $0 (2022) |
| GlaxoSmithKline, LLC. | $54.48 | 3 | $0 (2023) |
| PUMA BIOTECHNOLOGY, INC. | $53.81 | 3 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $69.88 | 4 | Novartis Pharmaceuticals Corporation ($37.07) |
| 2023 | $477.98 | 24 | Mirati Therapeutics, Inc. ($100.67) |
| 2022 | $471.73 | 18 | Zimmer Biomet Holdings, Inc. ($104.00) |
| 2021 | $117.56 | 7 | Kite Pharma, Inc. ($36.14) |
| 2020 | $120.77 | 6 | Amgen Inc. ($56.34) |
| 2019 | $34.49 | 2 | PFIZER INC. ($21.20) |
| 2018 | $23.99 | 1 | McKesson Specialty Care Distribution, LLC ($23.99) |
| 2017 | $37.48 | 2 | Ipsen Biopharmaceuticals, Inc ($24.22) |
All Payment Transactions
64 individual payment records from CMS Open Payments — Page 1 of 3
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 09/17/2024 | Novartis Pharmaceuticals Corporation | KISQALI (Drug) | Food and Beverage | In-kind items and services | $13.71 | General |
| Category: Oncology | ||||||
| 08/21/2024 | Spectrum Pharmaceuticals Inc. | ROLVEDON (Drug) | Food and Beverage | In-kind items and services | $15.77 | General |
| Category: Oncology | ||||||
| 03/20/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $17.04 | General |
| 01/08/2024 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $23.36 | General |
| Category: Oncology | ||||||
| 08/30/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $18.76 | General |
| Category: Oncology | ||||||
| 08/02/2023 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $24.68 | General |
| Category: Oncology | ||||||
| 07/26/2023 | GlaxoSmithKline, LLC. | ZEJULA (Drug), JEMPERLI | Food and Beverage | In-kind items and services | $18.23 | General |
| Category: ONCOLOGY | ||||||
| 07/19/2023 | Novartis Pharmaceuticals Corporation | SCEMBLIX (Drug) | Food and Beverage | In-kind items and services | $18.20 | General |
| Category: Oncology | ||||||
| 07/13/2023 | Genentech USA, Inc. | Venclexta (Biological) | Food and Beverage | In-kind items and services | $18.85 | General |
| Category: BioOncology | ||||||
| 06/21/2023 | Amgen Inc. | LUMAKRAS (Drug) | Food and Beverage | In-kind items and services | $24.64 | General |
| Category: Oncology | ||||||
| 06/21/2023 | PFIZER INC. | BOSULIF (Drug), BESPONSA | Food and Beverage | In-kind items and services | $14.06 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 06/16/2023 | ARRAY BIOPHARMA INC | LORBRENA (Drug), BRAFTOVI, MEKTOVI | Food and Beverage | In-kind items and services | $20.55 | General |
| Category: ONCOLOGY | ||||||
| 06/14/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | In-kind items and services | $28.08 | General |
| Category: ONCOLOGY | ||||||
| 06/08/2023 | Novartis Pharmaceuticals Corporation | PROMACTA (Drug) | Food and Beverage | In-kind items and services | $22.40 | General |
| Category: Oncology | ||||||
| 06/07/2023 | AstraZeneca Pharmaceuticals LP | TAGRISSO (Drug) | Food and Beverage | In-kind items and services | $22.07 | General |
| Category: Oncology | ||||||
| 05/24/2023 | Alnylam Pharmaceuticals Inc. | GIVLAARI (Drug) | Food and Beverage | In-kind items and services | $13.55 | General |
| Category: Genetic Disease | ||||||
| 05/17/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $20.67 | General |
| Category: Oncology | ||||||
| 05/03/2023 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $18.87 | General |
| Category: Oncology | ||||||
| 04/19/2023 | Genentech USA, Inc. | Gazyva (Biological), Lunsumio, Polivy | Food and Beverage | In-kind items and services | $14.67 | General |
| Category: BioOncology | ||||||
| 04/13/2023 | Genentech USA, Inc. | Venclexta (Biological) | Food and Beverage | In-kind items and services | $17.43 | General |
| Category: BioOncology | ||||||
| 03/09/2023 | Lilly USA, LLC | VERZENIO (Drug), JAYPIRCA | Food and Beverage | In-kind items and services | $18.98 | General |
| Category: Oncology | ||||||
| 03/08/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Food and Beverage | In-kind items and services | $31.14 | General |
| Category: ONCOLOGY | ||||||
| 03/08/2023 | Mirati Therapeutics, Inc. | KRAZATI (Drug) | Education | In-kind items and services | $21.00 | General |
| Category: ONCOLOGY | ||||||
| 03/01/2023 | Amgen Inc. | Kyprolis (Drug) | Food and Beverage | In-kind items and services | $12.83 | General |
| Category: Oncology | ||||||
| 02/08/2023 | PFIZER INC. | BOSULIF (Drug), BESPONSA | Food and Beverage | In-kind items and services | $17.03 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 28 | 1,142 | 81,171 | $3.1M | $1.3M |
| 2022 | 26 | 1,081 | 76,212 | $2.9M | $1.4M |
| 2021 | 35 | 1,529 | 96,788 | $4.2M | $2.1M |
| 2020 | 37 | 1,624 | 179,979 | $4.4M | $2.0M |
Total Patients
5,376
Total Services
434,150
Medicare Billing
$6.9M
Procedure Codes
126
All Medicare Procedures & Services
126 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 19 | 20,000 | $1.5M | $856,398 | 57.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 52 | 12,240 | $367,200 | $224,430 | 61.1% |
| Q5122 | Injection, pegfilgrastim-apgf (nyvepria), biosimilar, 0.5 mg | Office | 2023 | 21 | 960 | $456,000 | $87,890 | 19.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 64 | 499 | $194,111 | $50,863 | 26.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 144 | 304 | $82,688 | $27,871 | 33.7% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 83 | 179 | $65,514 | $24,599 | 37.5% |
| 96374 | Injection of drug or substance into vein | Office | 2023 | 51 | 347 | $50,315 | $10,017 | 19.9% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 27 | 156 | $27,612 | $7,833 | 28.4% |
| Q0138 | Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 2023 | 20 | 20,401 | $61,203 | $7,739 | 12.6% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 44 | 44 | $23,132 | $7,537 | 32.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 98 | 111 | $20,535 | $6,511 | 31.7% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 72 | 130 | $22,490 | $6,191 | 27.5% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 39 | 360 | $20,160 | $4,347 | 21.6% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 86 | 362 | $22,806 | $4,014 | 17.6% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 37 | 170 | $13,600 | $3,830 | 28.2% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 17 | 163 | $12,551 | $3,591 | 28.6% |
| 96411 | Administration of additional new drug or substance into vein using push technique | Office | 2023 | 13 | 65 | $10,205 | $2,802 | 27.5% |
| J1453 | Injection, fosaprepitant, 1 mg | Office | 2023 | 29 | 18,900 | $56,700 | $2,265 | 4.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 18 | 18 | $7,524 | $2,077 | 27.6% |
| 96402 | Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 13 | 71 | $9,585 | $1,882 | 19.6% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 45 | 274 | $9,590 | $1,635 | 17.0% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 35 | 1,960 | $78,400 | $1,618 | 2.1% |
| J9045 | Injection, carboplatin, 50 mg | Office | 2023 | 15 | 424 | $2,120 | $824.13 | 38.9% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 11 | 11 | $495.00 | $332.53 | 67.2% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 38 | 2,358 | $2,358 | $229.28 | 9.7% |
About Dr. Stephen Williams, MD
Dr. Stephen Williams, MD is a Hematology & Oncology healthcare provider based in Roseburg, Oregon. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/01/2007. The National Provider Identifier (NPI) number assigned to this provider is 1437370947.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Stephen Williams, MD has received a total of $1,354 in payments from pharmaceutical and medical device companies, with $69.88 received in 2024. These payments were reported across 64 transactions from 30 companies. The most common payment nature is "Food and Beverage" ($1,290).
As a Medicare-enrolled provider, Williams has provided services to 5,376 Medicare beneficiaries, totaling 434,150 services with total Medicare billing of $6.9M. Data is available for 4 years (2020–2023), covering 126 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Roseburg, OR
- Active Since 05/01/2007
- Last Updated 02/20/2017
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1437370947
Products in Payments
- Fastframe (Device) $104.00
- KRAZATI (Drug) $100.67
- KEYTRUDA (Biological) $68.00
- DARZALEX (Biological) $62.19
- Vectibix (Biological) $56.34
- NERLYNX (Drug) $53.81
- BOSULIF (Drug) $52.29
- SCEMBLIX (Drug) $41.56
- OPDIVO (Biological) $39.43
- PROMACTA (Drug) $38.03
- Lenvima (Drug) $36.91
- Venclexta (Biological) $36.28
- XTANDI (Drug) $36.23
- ZEJULA (Drug) $33.17
- Kyprolis (Drug) $32.01
- Orserdu (Drug) $24.68
- LUMAKRAS (Drug) $24.64
- Dysport 300 U-1 (Drug) $24.22
- Cabometyx (Drug) $24.05
- ORGOVYX (Drug) $22.53
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.